Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: Results of a randomised, controlled trial

International Wound Journal

Volumn 5, Issue 2, 2008, Pages 172-182

  Schmutz, Jean Luc ^a   Meaume, Sylvie ^b   Fays, Ségolène ^a   Ourabah, Zohva ^b   Guillot, Bernard ^c   Thirion, Valéne ^d   Collier, Mark ^e   Barrett, Simon ^f   Smith, J ^g   Bohbot, Serge ^h   Dompmartin, Anne ⁱ  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔPITAL CHARLES FOIX   (France)

^c HÔPITAL SAINT ELOI   (France)

^d Léopold Bellan Hospital   (France)

^e PILGRIM HOSPITAL   (United Kingdom)

^f HULL ROYAL INFIRMARY   (United Kingdom)

^g Blandford Forum   (United Kingdom)

^h R and D Department ^*  (France)

ⁱ CHU Clemenceau   (France)

Author keywords

Metalloproteinase matrix (MMP); Nano oligosaccharide (NOSF); Randomised clinical trial; Venous leg ulcer

Indexed keywords

COLLAGEN; NANOOLIGOSACCHARIDE FACTOR; OLIGOSACCHARIDE; OXIDIZED REGENERATED CELLULOSE;

ADULT; AGED; ANKLE BRACHIAL INDEX; CLINICAL TRIAL; COLLOID; COMPRESSION BANDAGE; COMPRESSION THERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; WOUND CARE; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; BANDAGES, HYDROCOLLOID; COLLOIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; MIDDLE AGED; OLIGOSACCHARIDES; TIME FACTORS; VARICOSE ULCER; WOUND HEALING;

EID: 44349104854     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/j.1742-481X.2008.00453.x     Document Type: Conference Paper

References (48)

1. Nelzen O, Bergqvist D, Lindhagen A. Venous and non-venous leg ulcers: clinical history and appearance in a population study. Br J Surg 1994 81 : 182 7.
2. Graham ID, Harrison MB, Nelson EA, Lorimer K, Fisher A. Prevalence of lower-limb ulceration: a systematic review of prevalence studies. Adv Skin Wound Care 2003 16 : 305 16.
3. Walker NK, Vandal AC, Holden JK, Rodgers A, Birchall N, Norton R, Triggs CM, MacMahon S. Does capture-recapture analysis provide more reliable estimates of the incidence and prevalence of leg ulcers in the community? Aust N Z J Public Health 2002 26 : 451 5.
4. Marklund B, Sulau T, Lindholm C. Prevalence of non-healed and healed chronic leg ulcers in an elderly rural population. Scand J Prim Health Care 2000 18 : 58 60.
5. Nelzen O, Bergqvist D, Lindhagen A, Hallböök T. Chronic leg ulcers: an underestimated problem in primary health care among elderly patients. J Epidemiol Community Health 1991 45 : 184 7.
6. Callam MJ, Harper DR, Dale JJ. Chronic ulcer of the leg: clinical history. Br Med J (Clin Res Ed) 1987 294 : 1389 91.
7. Baker SR, Stacey MC. Epidemiology of chronic leg ulcers in Australia. Aust N Z J Surg 1994 64 : 258 61.
8. Steed DL, Hill DP, Woodske ME, Payne WG, Robson MC. Wound-healing trajectories as outcome measures of venous stasis ulcer treatment. Int Wound J 2006 3 : 40 7.
9. Steed DL. Wound-healing trajectories. Surg Clin North Am 2003 83 : 547 55, vi-vii.
10. Robson MC, Hill DP, Woodske ME, Steed DL. Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg 2000 135 : 773 7.
11. Whitney JD. Overview: acute and chronic wounds. Nurs Clin North Am 2005 40 : 191 205, v.
12. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005 366 : 1736 43.
13. Sibbald RG, Orsted H, Schultz GS, Coutts P, Keast D International Wound Bed Preparation Advisory Board; Canadian Chronic Wound Advisory Board. Preparing the wound bed 2003: focus on infection and inflammation. Ostomy Wound Manage 2003 49 : 23 51.
14. Mulder GD, Vande Berg JS. Cellular senescence and matrix metalloproteinase activity in chronic wounds. Relevance to debridement and new technologies. J Am Podiatr Med Assoc 2002 92 : 34 7.
15. Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann Med 2002 34 : 419 27.
16. Murphy MO, Ghosh J, Fulford P, Khwaja N, Halka AT, Carter A, Turner NJ, Walker MG. Expression of growth factors and growth factor receptor in non-healing and healing ischaemic ulceration. Eur J Vasc Endovasc Surg 2006 31 : 516 22.
17. Chan RK, Liu PH, Pietramaggiori G, Ibrahim SI, Hechtman HB, Orgill DP. Effect of recombinant platelet-derived growth factor (Regranex) on wound closure in genetically diabetic mice. J Burn Care Res 2006 27 : 202 5.
18. Ovington LG. Overview of matrix metalloprotease modulation and growth factor protection in wound healing. Part 1. Ostomy Wound Manage 2002 48 (6 Suppl 3 7.
19. James TJ, Hughes MA, Cherry GW, Taylor RP. Evidence of oxidative stress in chronic venous ulcers. Wound Repair Regen 2003 11 : 172 6.
20. Mwaura B, Mahendran B, Hynes N, Defreitas D, Avalos G, Adegbola T, Adham M, Connolly CE, Sultan S. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 2006 31 : 306 10.
21. Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications 2006 20 : 329 35.
22. Clarke-Moloney M, Lyons GM, Burke PE, O'Keeffe D, Grace PA. A review of technological approaches to venous ulceration. Crit Rev Biomed Eng 2005 33 : 511 56.
23. Harding KG, Moore K, Phillips TJ. Wound chronicity and fibroblast senescence - implications for treatment. Int Wound J 2005 2 : 364 8.
24. O'Donnell TF Jr., Lau J. A systematic review of randomized controlled trials of wound dressings for chronic venous ulcer. J Vasc Surg 2006 44 : 1118 25.
25. Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers. Cochrane Database Syst Rev 2006 3 : CD001103.
26. Coulomb B, Couty L, Fournier B, Laurensou C, Aillaud C, Gogly B, Lafont A, Evaluation de la matrice lipido-colloide NOSF (nano-oligosaccharide factor), dans un modèle de reconstruction dermique in vitro. Oral communication presented in « 12ème Conference Nationale des Plaies et Cicatrisations », Paris, January 2008.
27. Vin F, Teot L, Meaume S. The healing properties of Promogran in venous leg ulcers. J Wound Care 2002 11 : 335 41.
28. Wiens BL. Choosing an equivalence limit for noninferiority or equivalence studies. Control Clin Trials 2002 23 : 2 14.
29. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006 295 : 1152 60.
30. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA 2006 295 : 1147 51.
31. Xue M, Le NT, Jackson CJ. Targeting matrix metalloproteases to improve cutaneous wound healing. Expert Opin Ther Targets 2006 10 : 143 55.
32. Medina A, Scott PG, Ghahary A, Tredget EE. Pathophysiology of chronic nonhealing wounds. J Burn Care Rehabil 2005 26 : 306 19.
33. Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc 2002 92 : 12 18.
34. Herouy Y, Trefzer D, Zimpfer U, Schöpf E, Wanscheidt W, Norgauer J. Matrix metalloproteinases and venous leg ulceration. Eur J Dermatol 2000 10 : 173 80.
35. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 1996 107 : 743 8.
36. Weckroth M, Vaheri A, Lauharanta J, Sorsa T, Konttinen YT. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J Invest Dermatol 1996 106 : 1119 24.
37. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002 10 : 16 25.
38. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002 137 : 822 7.
39. Chaby G, Viseux V, Ramelet AA, Ganry O, Billet A. Refractory venous leg ulcers: a study of risk factors. Dermatol Surg 2006 32 : 512 9.
40. Gohel MS, Taylor M, Earnshaw JJ, Heather BP, Poskitt KR, Whyman MR. Risk factors for delayed healing and recurrence of chronic venous leg ulcers - an analysis of 1324 legs. Eur J Vasc Endovasc Surg 2005 29 : 74 7.
41. Skene AI, Smith JM, Doré CJ, Charlett A, Lewis JD. Venous leg ulcers: a prognostic index to predict time to healing. BMJ 1992 305 : 1119 21.
42. Gelfand JM, Hoffstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers. J Invest Dermatol 2002 119 : 1420 5.
43. Kantor J, Margolis DJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol 2000 142 : 960 4.
44. Margolis DJ, Berlin JA, Strom BL. Which venous leg ulcers will heal with limb compression bandages? Am J Med 2000 109 : 15 9.
45. Phillips TJ, Machado F, Trout R, Porter J, Olin J, Falanga V. Prognostic indicators in venous ulcers. J Am Acad Dermatol 2000 43 : 627 30.
46. Letouze A, Voinchet V, Hoecht B, Muenter KC, Vives F, Bohbot S. Using a new lipidocolloid dressing in paediatric wounds: results of French and German clinical studies. J Wound Care 2004 13 : 221 5.
47. Meaume S, Ourabah Z, Cartier H, Granel-Brocard F, Bressieux JM, Bohbot S. Evaluation of a lipidocolloid wound dressing in the local management of leg ulcers. J Wound Care 2005 7 : 329 34.
48. Smith J, Barrett S, Hayes W, Kirby P, Walsh S, Gittins E, Whitehurst F, Cooper R. Evaluation of Urgotul® plus K-Four compression for venous leg ulcers. Br J Nurs 2004 13 (TVN Suppl S20 8.